Biocon Biologics gets EU GMP certificate for new Bengaluru facility

Biocon Biologics Ltd., a subsidiary of Biocon Ltd. has announced that the company has received an EU GMP certificate from the Health Products Regulatory Authority (HPRA), Ireland, for its new monoclonal antibodies (mAbs) drug substance manufacturing facility (B3) at Biocon Park, Bengaluru, following a GMP inspection in April 2022.

"The facility, spread across 340,000-square feet, will enhance our capabilities manifold to manufacture drug substance of our mAbs portfolio and will enable us to serve patients across the globe," the company's spokesperson stated.

For more details, check out the full story on the link below:

Biocon Arm Bags EU GMP Certification For New Bengaluru Facility